Editor-We read with great interest the study by Compton and colleagues 1 comparing minimal invasive measurements of cardiac output obtained with two devices, the PiCCO TM and the FloTrac TM /Vigileo TM system. The latter has been introduced into clinical practice in 2005, and early studies comparing this device with established methods to determine cardiac output have shown limited agreement only. As a consequence, the algorithm for calculating stroke volume, heart rate, and hence cardiac output derived from the arterial pressure waveform ( pulse contour analysis) has been modified and several software updates have been released. Compton and colleagues claim that they used the new, improved software version named 1.10, which was released in November 2006, and not in spring 2006 as stated. On the other hand, patients were included between July 2006 and May 2007. Thus, the question arises which software version was really used or how many of their 25 patients were studied using the latest software update. This question is of importance as the updated software resulted in an improved percentage error of measurement values compared with standard techniques (Table 1, which updates Table 4 from the original article). One of the software updates refers to the detection of arrhythmias, eliminating one of the study limitations raised by the authors. A second point refers to the data presentation. In the Method section, the authors claim that both the transpulmonary thermodilution-derived cardiac output and the pulse contour-derived continuous cardiac output values of the PiCCO TM system were used for comparison with the new device. However, in the Results section, no comparison between both pulse contourderived methods is presented. Instead, PiCCO TM data obtained from transpulmonary thermodilution and pulse contour analysis were pooled. It would be interesting to see the agreement between data obtained from transpulmonary thermodilution and pulse contour analysis obtained with the PiCCO TM . Finally, we wonder if transpulmonary thermodilution is a good choice for obtaining reference values for cardiac output, particularly in patients with acute lung injury, as the femoral thermodilution curve is likely affected by pulmonary oedema. In the Compton study, 19 of the 25 patients suffered from acute respiratory failure. The authors state that re-calibration of the PiCCO TM device was done at least every 24 h. A recent paper has shown that the accuracy of obtained values exceeds the accepted percentage error of 30% 2 as early as 60 min after re-calibration. 3 Hence, a frequent recalibration of the PiCCO TM device (every 20-30 min) is required to obtain reliable results, particularly in the presence of vasopressor therapy. 4 In their discussion, the authors state that arrhythmia was a 'limitation', but provide no information regarding its incidence. In this respect, it is noteworthy that the key feature of the latest software version (v1.10) is the improved performance during arrhythmia.
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In conclusion, we challenge the conclusions presented by the authors concerning the (lack of ) accuracy of the FloTrac TM /Vigileo TM system since they obviously did not consistently use the improved new software version throughout their study as stated. Furthermore, the inappropriate choice and use of the reference method precludes expecting a close agreement between the two techniques.
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